SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Company Response from PALISADE BIO, INC. (PALI) (CIK 0001357459) (PALI) — Dec 16, 2008

PALISADE BIO, INC. (PALI) (CIK 0001357459)
Date: Dec. 16, 2008 · CIK: 0001357459 · Accession: 0001144204-08-069723

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 001-33672

Date
December 31, 2007
Author
John Conron
Form
CORRESP
Company
PALISADE BIO, INC. (PALI) (CIK 0001357459)

Letter

Neuralstem, Inc. Form 10-KSB for the Fiscal Year Ended December 31, 2007 Filed March 27, 2008 File No. 001-33672

Dear Mr. Rosenberg:

We are submitting this letter in response to your comments of December 4, 2008, with respect to Neuralstem, Inc. (“Company”) annual report referenced above. This response will follow the lineal order of your letter and each specific area addressed, utilizing the text of your letter as the primary guide:

Form l0-KSB for the fiscal year ended December 31, 2007

Report of Independent Registered Public Accounting Finn, page F-l

1.

Please confirm that you received a signed audit report by Stegman & Company as required by Rule 2-02(a) of Regulation S-X and Rule 232.302 of Regulation S-T and tell us whether you will include a signed audit report in your future filings.

Response:

We are hereby confirming that we received a signed audit report from Stegman & Company as required by Rule 2-02(a) of Regulation S-X and Rule 232.302 of Regulation S-T. We are also confirming that we will include a signed audit report in our future filings.

NEURALSTEM, INC.

GREAT SENECA HIGHWAY, SUITE 240

ROCKVILLE, MD 20850

(301) 366-4841

We hereby acknowledge that:

1.

the company is responsible for the adequacy and accuracy of the disclosure in the filing;

2.

staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to filing; and

3.

the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities law of the United States

Very
truly yours,
/s/
John Conron

Show Raw Text
CORRESP
1
filename1.htm

    Unassociated Document

      NEURALSTEM,
INC.

      9700
GREAT SENECA HIGHWAY, SUITE 240

      ROCKVILLE,
MD 20850

      (301)
366-4841

    December
17, 2008

    SENT VIA
EDGAR

    Jim B.
Rosenberg

    Senior
Assistant Chief Accountant

    Telephone
Number: (202) 551-3679

                    RE:

                    Neuralstem,
      Inc.

    Form
10-KSB for the Fiscal Year Ended December 31, 2007

    Filed
March 27, 2008

    File
No. 001-33672

    Dear Mr.
Rosenberg:

    We are
submitting this letter in response to your comments of December 4, 2008, with
respect to Neuralstem, Inc. (“Company”) annual report referenced
above.  This response will follow the lineal order of your letter and
each specific area addressed, utilizing the text of your letter as the primary
guide:

    Form l0-KSB for the fiscal
year ended December 31, 2007

      Report of Independent
Registered Public Accounting Finn, page F-l

              1.

              Please
      confirm that you received a signed audit report by Stegman & Company
      as required by Rule 2-02(a) of Regulation S-X and Rule 232.302 of
      Regulation S-T and tell us whether you will include a signed audit report
      in your future filings.

              Response:

              We are hereby
      confirming that we received a signed audit report from Stegman &
      Company as required by Rule 2-02(a) of Regulation S-X and Rule 232.302 of
      Regulation S-T.  We are also confirming that we will include a
      signed audit report in our future
  filings.

      NEURALSTEM,
INC.

      9700
GREAT SENECA HIGHWAY, SUITE 240

      ROCKVILLE,
MD 20850

      (301)
366-4841

    We hereby
acknowledge that:

                  1.

                  the
      company is responsible for the adequacy and accuracy of the disclosure in
      the filing;

                  2.

                  staff
      comments or changes to disclosure in response to staff comments do not
      foreclose the Commission from taking any action with respect to filing;
      and

                3.

                the
      company may not assert staff comments as a defense in any proceeding
      initiated by the Commission or any person under the federal securities law
      of the United States

                                            Very
truly yours,

                                            /s/
John Conron

                                            John
Conron

                                            Chief
Financial Officer